Trials / Terminated
TerminatedNCT01902290
Study of Efficacy and Safety of Brodalumab Compared With Placebo in Adults With Inadequately Controlled Asthma With High Bronchodilator Reversibility
A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of Brodalumab in Subjects With Inadequately Controlled Asthma and High Bronchodilator Reversibility
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 421 (actual)
- Sponsor
- Amgen · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine if brodalumab (AMG 827) is safe and effective compared to placebo as measured by change in Asthma Control Questionnaire (ACQ) composite scores.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Placebo | Placebo administered subcutaneously |
| BIOLOGICAL | Brodalumab | Brodalumab administered subcutaneously |
Timeline
- Start date
- 2013-05-22
- Primary completion
- 2015-05-15
- Completion
- 2015-05-15
- First posted
- 2013-07-18
- Last updated
- 2022-09-21
- Results posted
- 2022-02-28
Locations
161 sites across 15 countries: United States, Australia, Canada, France, Germany, Greece, Hong Kong, Ireland, Italy, New Zealand, Poland, Puerto Rico, Russia, South Korea, Taiwan
Source: ClinicalTrials.gov record NCT01902290. Inclusion in this directory is not an endorsement.